Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.

被引：0
|
作者：
Zanwar, Saurabh
Sidana, Surbhi
Shune, Leyla
Alexis, Omar
Puglianini, Castaneda
Pasvolsky, Oren
Gonzalez, Rebecca
Dima, Danai
Afrough, Aimaz
Kaur, Gurbakhash
Davis, James A.
Herr, Megan
Hashmi, Hamza
Forsberg, Peter A.
Sborov, Douglas W.
Richard, Shambavi
Khouri, Jack
Lin, Yi
Patel, Krina K.
Kumar, Shaji
Hansen, Doris K.
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Stanford Univ, Med Ctr, Palo Alto, CA USA
[3] Univ Kansas, Med Ctr, Kansas City, KS USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA
[7] UT Southwestern Med Ctr, Dallas, TX USA
[8] Univ South Carolina, Charleston, SC USA
[9] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[10] Univ Colorado, Sch Med, Aurora, CO USA
[11] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[12] Icahn Sch Med Mt Sinai, New York, NY USA
[13] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7508
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
    Zanwar, Saurabh
    Sidana, Surbhi
    Shune, Leyla
    Puglianini, Omar Castaneda
    Pasvolsky, Oren
    Gonzalez, Rebecca
    Dima, Danai
    Afrough, Aimaz
    Kaur, Gurbakhash
    Davis, James A.
    Herr, Megan
    Hashmi, Hamza
    Forsberg, Peter
    Sborov, Douglas
    Anderson Jr, Larry D.
    McGuirk, Joseph P.
    Wagner, Charlotte
    Lieberman-Cribbin, Alex
    Rossi, Adriana
    Freeman, Ciara L.
    Locke, Frederick L.
    Richard, Shambavi
    Khouri, Jack
    Lin, Yi
    Patel, Krina K.
    Kumar, Shaji K.
    Hansen, Doris K.
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [2] Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Madduri, Deepu
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Lin, Yi
    Siegel, David
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Cavo, Michele
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Rambaldi, Alessandro
    Reece, Donna
    Petrocca, Fabio
    Massaro, Monica
    Connarn, Jamie N.
    Kaiser, Shari
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08): : 705 - 716
  • [3] Idecabtagene Vicleucel in Relapsed Myeloma
    Kidoguchi, Keisuke
    Mori, Jinichi
    Tanimoto, Tetsuya
    Quintas-Cardama, Alfonso
    Munshi, Nikhil C.
    Hege, Kristen
    San-Miguel, Jesus
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (24): : 2356 - 2357
  • [4] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
    Melody, Megan
    Przybylski, Daniel
    Robinson, Adam
    Lin, Adam
    Gordon, Leo
    Adekola, Kehinde
    Singhal, Seema
    Mehta, Jayesh
    Moreira, Jonathan
    [J]. BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211
  • [5] The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
    Oriol, Albert
    Abril, Laura
    Torrent, Anna
    Ibarra, Gladys
    Ribera, Josep-Maria
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [6] FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
    Sharma, Poornima
    Kanapuru, Bindu
    George, Bindu
    Lin, Xue
    Xu, Zhenzhen
    Bryan, Wilson W.
    Pazdur, Richard
    Theoret, Marc R.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (09) : 1759 - 1764
  • [7] Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances
    Tu, Wei
    Xiao, Yajuan
    Wang, Yadong
    Luo, Rongcheng
    Chen, Zhe-Sheng
    [J]. DRUGS OF TODAY, 2022, 58 (03) : 117 - 132
  • [8] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Buthainah Ghanem
    Lu Shi
    [J]. Clinical Drug Investigation, 2022, 42 : 1085 - 1092
  • [9] Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
    Oswald, Laura B.
    Gudenkauf, Lisa M.
    Li, Xiaoyin
    De Avila, Gabriel
    Peres, Lauren C.
    Kirtane, Kedar
    Gonzalez, Brian D.
    Hoogland, Aasha I.
    Nguyen, Oanh
    Rodriguez, Yvelise
    Baz, Rachid C.
    Shain, Kenneth H.
    Alsina, Melissa
    Locke, Frederick L.
    Freeman, Ciara
    Castaneda Puglianini, Omar
    Nishihori, Taiga
    Liu, Hien
    Blue, Brandon
    Grajales-Cruz, Ariel
    Jim, Heather S. L.
    Hansen, Doris K.
    [J]. CANCERS, 2023, 15 (19)
  • [10] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Ghanem, Buthainah
    Shi, Lu
    [J]. CLINICAL DRUG INVESTIGATION, 2022, 42 (12) : 1085 - 1092
12345